Ralometostat

Small molecule

Also known as TNG908

DiscontinuedPRMT5
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued, as a strategic decision by the sponsor

The company announced it stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization, and later referenced the discontinuation of the TNG908 clinical program. Company Form 10-Q; approved in the freshness review queue. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Other / comorbidity

Competitive landscape

6 other tracked programmes target this mechanism, 6 of them ahead of this one.

This drug's own stage for Glioblastoma: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ralometostat: this drugDiscontinuedSmall moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)not yet gradedNo reviewed efficacy summary in this indication
NiraparibPhase 3Small moleculePARP1/2not yet gradedNo reviewed efficacy summary in this indication
AZD3470
Phase 1/2(overall)
Small moleculePRMT5
not yet graded(overall)
No reviewed efficacy summary in this indication
BAY 3713372
Phase 1/2(overall)
Small moleculePRMT5
not yet graded(overall)
No reviewed efficacy summary in this indication
TemferonPhase 1/2Gene therapy / editingInterferon-alpha2 (myeloid-specific expression), Interferon-alpha2 (IFN-alpha2) expression in myeloid cellsnot yet gradedNo reviewed efficacy summary in this indication
TNG456Phase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
Vopimetostat
Phase 1/2(overall)
Small moleculePRMT5
not yet graded(overall)
No reviewed efficacy summary in this indication
ZedoresertibPhase 1/2Small moleculeWEE1 kinasenot yet gradedNo reviewed efficacy summary in this indication
AZD1390Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
HSK41959
Phase 1(overall)
Small moleculePRMT5
not yet graded(overall)
No reviewed efficacy summary in this indication
IDE892
Phase 1(overall)
Small moleculePRMT5
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.